Amgen Inc. with ticker code (AMGN) have now 27 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $405.00 and $200.00 calculating the average target share price we see $334.06. (at the time of writing). Now with the previous closing price of $301.44 this indicates there is a potential upside of 10.8%. The 50 day MA is $321.59 and the 200 day MA is $306.70. The total market capitalization for the company now stands at 159.07B. The price for the stock stands currently at: $295.93 USD
The potential market cap would be $176,285,763,900 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 37.75, revenue per share of $60.64 and a 4.6% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
